Media headlines about BioMarin Pharmaceutical (NASDAQ:BMRN) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BioMarin Pharmaceutical earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.8738796822011 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:
Several equities research analysts recently weighed in on BMRN shares. SunTrust Banks upped their price objective on shares of BioMarin Pharmaceutical to $130.00 and gave the stock a “buy” rating in a report on Monday, December 11th. Goldman Sachs Group raised shares of BioMarin Pharmaceutical from a “buy” rating to a “conviction-buy” rating in a report on Friday, December 15th. Zacks Investment Research downgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a report on Monday, October 16th. JPMorgan Chase & Co. set a $130.00 price objective on BioMarin Pharmaceutical and gave the stock a “buy” rating in a report on Sunday, October 29th. Finally, Morgan Stanley restated an “overweight” rating and set a $117.00 price objective (up previously from $115.00) on shares of BioMarin Pharmaceutical in a report on Friday, October 6th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $112.32.
Shares of BioMarin Pharmaceutical (NASDAQ BMRN) opened at $90.22 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.91 and a quick ratio of 3.81. The firm has a market capitalization of $15,844.53, a P/E ratio of -100.24 and a beta of 1.82. BioMarin Pharmaceutical has a 12-month low of $80.10 and a 12-month high of $100.51.
BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, October 26th. The biotechnology company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.06. The business had revenue of $334.18 million during the quarter, compared to analyst estimates of $347.38 million. BioMarin Pharmaceutical had a negative return on equity of 4.60% and a negative net margin of 12.45%. BioMarin Pharmaceutical’s revenue was up 19.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.02 earnings per share. sell-side analysts anticipate that BioMarin Pharmaceutical will post -0.64 EPS for the current fiscal year.
In other BioMarin Pharmaceutical news, EVP George Eric Davis sold 1,200 shares of the stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $85.64, for a total transaction of $102,768.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Jean Jacques Bienaime sold 10,000 shares of the stock in a transaction on Friday, January 5th. The stock was sold at an average price of $90.32, for a total value of $903,200.00. Following the transaction, the chief executive officer now owns 235,894 shares of the company’s stock, valued at $21,305,946.08. The disclosure for this sale can be found here. Insiders sold 60,750 shares of company stock valued at $5,439,788 over the last 90 days. 1.85% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect BioMarin Pharmaceutical (BMRN) Share Price” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/01/14/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-biomarin-pharmaceutical-bmrn-stock-price.html.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.